These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1291319)

  • 21. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
    Jackson GG; Paul DA; Falk LA; Rubenis M; Despotes JC; Mack D; Knigge M; Emeson EE
    Ann Intern Med; 1988 Feb; 108(2):175-80. PubMed ID: 3124680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HIV-correlated antigens and antibodies in patients treated with zidovudine].
    Garavelli PL; Dallavalle FM
    Minerva Med; 1990; 81(7-8 Suppl):93-4. PubMed ID: 2216047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zidovudine treatment of AIDS and ARC in Denmark 1987.
    Teglbjaerg LL; Mathiesen LR; Søeberg B; Nielsen L; Thorsen B; Buhl M; Pedersen C; Bonnevie O; Nielsen C; Vestergaard BF
    Scand J Infect Dis; 1989; 21(4):367-73. PubMed ID: 2685984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine.
    Jacobson MA; Abrams DI; Volberding PA; Bacchetti P; Wilber J; Chaisson RE; Crowe S; Howard W; Moss A
    J Infect Dis; 1989 Jun; 159(6):1029-36. PubMed ID: 2566637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.
    Murray HW; Squires KE; Weiss W; Sledz S; Sacks HS; Hassett J; Cross A; Anderson RE; Dunkle LM
    J Infect Dis; 1995 Mar; 171 Suppl 2():S123-30. PubMed ID: 7861017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
    Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
    Mulder JW; Lange JM; de Wolf F; Houweling JT; Bakker M; Coutinho RA; Goudsmit J
    Neth J Med; 1990 Aug; 37(1-2):4-10. PubMed ID: 2120599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
    Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):473-9. PubMed ID: 7632462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
    Richman DD; Grimes JM; Lagakos SW
    J Acquir Immune Defic Syndr (1988); 1990; 3(8):743-6. PubMed ID: 2114476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24.
    Schmidt G; Amiraian K; Frey H; Wethers J; Stevens RW; Berns DS
    J Clin Microbiol; 1989 May; 27(5):843-8. PubMed ID: 2501350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.
    Fischl MA; Richman DD; Causey DM; Grieco MH; Bryson Y; Mildvan D; Laskin OL; Groopman JE; Volberding PA; Schooley RT
    JAMA; 1989 Nov; 262(17):2405-10. PubMed ID: 2677429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex.
    Glaser JB; Volpe S; Aguirre A; Simpkins H; Schiffman G
    J Infect Dis; 1991 Oct; 164(4):761-4. PubMed ID: 1894937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy.
    Sasomsin P; Mentré F; Diquet B; Simon F; Brun-Vezinet F
    Fundam Clin Pharmacol; 2002 Oct; 16(5):347-52. PubMed ID: 12602459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
    Gallant JE; Moore RD; Keruly J; Richman DD; Chaisson RE
    J Infect Dis; 1995 Aug; 172(2):346-52. PubMed ID: 7622876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
    Reddy MM; Grieco MH; McKinley GF; Causey DM; van der Horst CM; Parenti DM; Hooton TM; Davis RB; Jacobson MA
    J Infect Dis; 1992 Sep; 166(3):607-10. PubMed ID: 1323624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
    AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.